Bio Assays - Commentary – First Supplement to USP 35-NF 30
Amongst others, the USP published the received comments and responses to General Chapter/Section: <1032> Design and Development of Biological Assays in the Commentary – First Supplement to USP 35-NF 30.
The USP received 13 comments to different parts of this chapter. Comments to the following topics are included:
- Necessary Harmonization with compendial references e.g. European Pharmacopoiea
- Helpful case study examples that illustrate the application
- The need that the assay acheive a specific observable response
- Assessment of similarity using the entire concentration-response curve, including the asymptotes.
- Potency assay for assessment of stability
- Need of documenting the source of assay's cell line
The complete comments can be found at Commentary – First Supplement to USP 35-NF 30.
In this respect you may also want to pay attention to ECA's New Education Course on "Bioassays, and Bioanalytics" from 27-28 March 2012 in Copenhagen, Denmark.
Author:
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
23.04.2025OTC Drug Production Ceased after FDA Warning Letter
23.04.2025EMA publishes Draft of ICH M13B Guideline on Bioequivalence
16.04.2025EMA publishes four new product-specific Bioequivalence Guidance
09.04.2025Missing Tests and Altered Records: FDA Warns Chinese OTC Manufacturer
09.04.2025Pharmeuropa: New Chapter on Evaporative Light-Scattering Detection published for Comment
09.04.2025Pharmeuropa: Four Draft Chapters on Elemental Analysis Published for Comment